The 7investing Podcast

Daniel Anstandig, the CEO and Co-Founder of Futuri -- an innovative company focusing on enhancing the effectiveness of media through an enterprise tech platform --  joined the 7investing podcast to explain what his company does and share his thoughts on the future of media. Futuri has targeted making content companies more effective. The emerging brand uses an artificial intelligence (AI) system to “detect stories bubbling to the surface that are going to go viral, allowing producers (podcasts, TV, online, radio) an opportunity to get ahead of the story and catch the news as it breaks. It also helps media target specific audiences, stories, demographics and more to make them more profitable.” That’s a goal that could help companies produce content that makes more money. It’s also a concept that some editorial professionals will bristle at. Anstandig explained how his product can work to benefit companies striving to create high-quality content. He also addressed some of the pitfalls that can happen when people overuse AI rather than using it as a tool to help them make better decisions. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

When Caribou Biosciences (NASDAQ: CRBU) became the seventh publicly-traded CRISPR stock in July 2021, I saw an exchange on social media. One person asked why the company sported a market valuation of $900 million when another newly-public CRISPR stock, Verve Therapeutics (NASDAQ: VERV), was valued near $2.3 billion. "Is there any reason for this other than the timing of the IPOs?", asked the individual. The thread received multiple responses confirming the seemingly large valuation difference between the two companies, with others "agreeing" or responding that they were buying Caribou Biosciences because of it. That was 100% the wrong take. I've observed similar arguments among individual investors within the gene editing space. However, it's important to acknowledge that there are significant differences between gene editing approaches and technology platforms. Caribou Biosciences and Verve Therapeutics might both be using CRISPR systems, but that's where the overlap ends. They're developing completely different tools that have almost nothing in common. Individual investors don't necessarily need to have a deep technical understanding of gene editing tools, but I would argue that there's a minimum level of information required to responsibly invest in the field. Unfortunately, the way the internet works means most investors aren't provided with the information they need. Let's fix that. In this episode of the podcast, 7investing Lead Advisors Maxx Chatsko (me) and Dan Kline introduce simple frameworks for evaluating opportunities and challenges in gene editing. These can be summarized as follows: The Emerging Approaches: There's first-generation tools (gene editing), second-generation tools (base editing), and third-generation tools (prime editing). These approaches are not limited to any specific system. For example, there are CRISPR, TALEN, ARCUS, and other tools capable of performing base editing. The Major Applications: There are knock outs, insertions, activations, precise corrections, knock ins, and other uses of gene editing tools. Each has advantages and disadvantages. The Major Administration Routes: This primarily comes down to in vivo (inside the body) and ex vivo (outside the body). Each has advantages and disadvantages. In addition to this podcast introducing the three frameworks, 7investing Lead Advisor Maxx Chatsko has written an in-depth article explaining these frameworks and how each gene editing stock fits into each -- and it's free to read! Publicly-traded companies mentioned in this podcast include Alnylam Pharmaceuticals, Beam Therapeutics, Caribou Biosciences, Cellectis, CRISPR Therapeutics, Editas Medicine, Graphite Bio, Intellia Therapeutics, Precision BioSciences, Sana Biotechnology, and Verve Therapeutics. 7investing Lead Advisors may have positions in the companies that are mentioned. This interview was originally recorded on August 2nd, 2021 and was first published on August 3rd, 2021.

Robinhood’s first day as a publicly-traded company didn’t quite go as planned. Is this company a long-term investment opportunity? 7investing lead advisors Dana Abramovitz and Simon Erickson analyze how Robinhood makes its money and whether those revenue streams are long-term sustainable. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

Markets have been propped up by low interest rates for quite some time, yet inflation looms on everyone’s mind. What could be the impact for long-term investors? 7investing lead advisors Maxx Chatsko and Steve Symington share their take on the Fed’s recent actions, the potential for transitory inflation, and certain pockets of the economy that are a bit ‘frothier’ than others. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

The world is adjusting to the new normal of the COVID pandemic. But what could resurging cases of its Delta variant mean for the stock market? 7investing lead advisors Anirban Mahanti and Dan Kline evaluate the impact of the pandemic on companies with international supply chains and share their advice for long-term investors. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

China is threatening stricter regulations on its businesses who are listed on American exchanges. What could this mean for long-term investors? 7investing Lead Advisors Maxx Chatsko and Simon Erickson dig into variable interest entities, what it means to be ‘delisted’, and what China is ultimately trying to achieve on the global stage. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

In a Sunday surprise Square reported its second quarter earnings and dropped the news that it will buy Australian buy-now-pay-later (BNPL) firm Afterpay for $29 billion. The all-stock transaction will give Afterpay shareholders 0.375 shares of Square class A stock for every share they own. That’s roughly a 30% premium from where shares closed at the end of the market day Friday. Anirban Mahanti and Simon Erickson join the Monday edition of 7investing Now to break down the deal and to explain what the move means for Square’s long-term plans. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

It has been a very busy earnings season and a lot of big tech companies have followed the same pattern -- report good, even great, numbers, then warn that the next quarter may see things slow down. That’s what happened with both Facebook and Amazon. The two companies ostensibly killed it, but they did warn that future growth won’t be as big. In addition, we’ll talk about whether Intel can complete its comeback and take on AMD in the fight for artificial intelligence dominance. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

Finding a stock that returns 100 times your initial investment might sound like an improbable dream for most investors. After all, who would think that anyone could possibly turn $10,000 into $1 million with any reasonable degree of certainty? In fact, there are hundreds of stocks that have done exactly that in recent years. And anyone can find them if they know what to look for. In his book, “100 Baggers: Stocks That Return 100-to-1 and How To Find Them,” author, portfolio manager, and Woodlock House Family Capital co-founder Chris Mayer focuses on the characteristics shared by the remarkable companies underlying these stocks, and the challenges investors face buying and to realize life-changing returns. This week 7investing Lead Advisor Steve Symington sat down to down to talk with Chris about his own portfolio-management style, the most common traits of 100-bagger stocks, and how anyone can find them with patience and a long-term mindset. Stocks discussed include: Teledyne (NYSE: TDY), Monster Beverage (NASDAQ: MNST), Starbucks (NASDAQ: SUBX), Amazon.com (NASDAQ: AMZN), Square (NYSE: SQ), Apple (NASDAQ: AAPL), Coca-Cola (NYSE: KO), AutoZone (NYSE: AZO), Constellation Software (TSE: CFU), Berkshire Hathaway (NYSE: BRK-A)(NYSE: BRK-B), Pfizer (NYSE: PFE), Intuit (NASDAQ: INTU), NVIDIA (NASDAQ: NVDA), McDonald's (NYSE: MCD) Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing

Tesla kicked off earnings season with some strong numbers despite having to manage supply chain issues related to the chip shortage. Apple followed that with some blockbuster numbers but shares in the tech giant fell because it warned that chip shortages could impact its iPhone output. Starbucks had a similar trajectory with the company delivering strong numbers but warning that it expects weakness in China in the next quarter. Microsoft closes out our quartet of companies with its own blockbuster numbers and some mildly negative news that may overshadow the good news. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us on Social Media ► https://www.facebook.com/7investing/ ► https://twitter.com/7investing ► https://instagram.com/7investing